Previous Article | Next Article 
Infection and Immunity, November 1998, p. 5067-5072, Vol. 66, No. 11
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
A Chlamydia pneumoniae Component That
Induces Macrophage Foam Cell Formation Is Chlamydial
Lipopolysaccharide
Murat V.
Kalayoglu, and
Gerald I.
Byrne*
Department of Medical Microbiology and
Immunology, University of Wisconsin Medical School, Madison,
Wisconsin 53706
Received 7 May 1998/Returned for modification 15 July 1998/Accepted 12 August 1998
 |
ABSTRACT |
Chlamydia pneumoniae infection is associated with
atherosclerotic heart and vessel disease, but a causal relationship
between this pathogen and the disease process has not been established. Recently, it was reported that C. pneumoniae induces human
macrophage foam cell formation, a key event in early atheroma
development, suggesting a role for the organism in atherogenesis. This
study further examines C. pneumoniae-induced foam cell
formation in the murine macrophage cell line RAW-264.7. Infected RAW
cells accumulated cholesteryl esters when cultured in the presence of low-density lipoprotein in a manner similar to that described for human
macrophages. Exposure of C. pneumoniae elementary bodies to
periodate, but not elevated temperatures, inhibited cholesteryl ester
accumulation, suggesting a role for chlamydial lipopolysaccharide (cLPS) in macrophage foam cell formation. Purified cLPS was found to be
sufficient to induce cholesteryl ester accumulation and foam cell
formation. Furthermore, the LPS antagonist lipid X inhibited C. pneumoniae and cLPS-induced lipid uptake. These data indicate that cLPS is a C. pneumoniae component that induces
macrophage foam cell formation and suggest that infected macrophages
chronically exposed to cLPS may accumulate excess cholesterol to
contribute to atheroma development.
 |
INTRODUCTION |
Atherosclerosis is a chronic,
inflammatory disease that results from arterial hemodynamic changes and
complex interactions between a variety of lipids, cell types, and their
soluble mediators (39, 44). The central cell mediating
atheroma development may be the macrophage (32, 48).
Atheroma macrophages accumulate excess cholesterol that is esterified
and stored in the cytoplasm, and these cholesteryl ester-loaded
macrophages, or foam cells, are the hallmark of early fatty streak
lesions in atherogenesis (4).
Although multiple risk factors for atherosclerosis have been identified
(21, 45, 46), 30 to 40% of disease complications result in
the absence of these conditions and may involve previously unrecognized
risk factors. Appreciation of atherosclerosis as an inflammatory
disease (29, 38, 39) has renewed interest in the role that
infectious agents may play in atheroma development. In particular, the
obligate intracellular bacterium Chlamydia pneumoniae has
been associated with atherosclerosis by seroepidemiology (41), identification of the organism within atheromas by
immunohistochemistry (23) and within foam cells by electron
microscopy (43), and identification of the C. pneumoniae genome within atheromas by PCR (24). In
addition, the organism has been isolated from atheromas (19), and antibiotic treatment trials have shown significant reductions of complications in patients with atherosclerosis (15, 16).
Although ample clinical data exist to suggest a role for C. pneumoniae in atherosclerosis, how the organism may initiate or promote the disease remains unclear. Rabbit and apolipoprotein E-deficient murine animal models have been developed to study atherosclerosis following C. pneumoniae infection (30,
31) and may prove useful to examine mechanisms of disease in
vivo. In vitro, C. pneumoniae has been shown to infect and
multiply within smooth muscle cells, endothelial cells, and macrophages (12), suggesting that the organism can survive and persist
within atheromas. Furthermore, infected mononuclear cells release
inflammatory cytokines (22) that may contribute indirectly
to atheroma development.
Evidence linking C. pneumoniae infection to events thought
to contribute directly to atherogenesis has emerged only recently. C. pneumoniae has been shown to induce human macrophage foam
cell formation when cultured in the presence of low-density lipoprotein (LDL) (20), implicating this organism as a causative agent
in atherosclerosis. However, detailed characterization of C. pneumoniae-induced foam cell formation by human monocyte-derived
macrophages has been difficult due to the widely varying capacity to
ingest lipids by monocytes/macrophages isolated from different
subjects. In this study, we used the well-characterized murine
macrophage cell line RAW-264.7 to further examine the role of C. pneumoniae in foam cell formation by macrophages.
 |
MATERIALS AND METHODS |
Reagents.
Cholesterol esterase was purchased from Boehringer
Mannheim (Indianapolis, Ind.). Highly purified C. trachomatis chlamydial lipopolysaccharide (cLPS) extracted by the
Galanos method (10), as modified by Qureshi et al. (18,
34), was kindly provided by Douglas Golenbock (Boston, Mass.).
The purity of cLPS was determined by protein assay, thin-layer
chromatography, and high-pressure liquid chromatography
(18). Escherichia coli lipid X was synthesized by
Peter Stutz (Vienna, Austria) and was a gift from Richard Proctor and
Loren Denlinger (Madison, Wis.). All other reagents were purchased from
Sigma Chemical Company (St. Louis, Mo.).
Isolation of LDL.
LDL was isolated from normolipidemic
donors by density gradient ultracentrifugation as previously described
(37), extensively dialyzed against 0.15 M NaCl-0.05% EDTA,
and concentrated by centrifugation in Centri/Por concentrators
(Spectrum, Houston, Tex.). LDL protein and cholesterol were determined
by use of a protein assay (Bio-Rad, Hercules, Calif.) and a total
cholesterol test kit (Sigma), respectively. Sodium dodecyl
sulfate-polyacrylamide gel electrophoresis analysis of LDL on a 4 to
20% gradient gel revealed a single protein (molecular weight,
~250,000) consistent with LDL apolipoprotein B-100. Agarose gel
electrophoresis of LDL showed no increase in relative electrophoretic mobility within 2 weeks, indicating that isolated LDL did not become
oxidized (8). Isolated LDL was stored at 4°C and used within 2 weeks of isolation.
Propagation of chlamydiae and growth of macrophages.
C.
pneumoniae was purchased from the American Type Culture Collection
(ATCC) (Manassas, Va.), propagated in HEp-2 cells (ATCC), and purified
by Renografin gradient centrifugation as previously described
(6). Propagated organisms were stored at
70°C in sucrose
buffer and titered for infectivity as described (20). Titers
are reported here as multiplicity of infection (MOI), where one MOI
equals one infectious Chlamydia organism/HEp-2 cell.
The murine macrophage cell line RAW-264.7 (ATCC) was grown in RPMI 1640 medium (BioWhittaker, Walkersville, Md.) supplemented with 10% fetal
bovine serum (FBS; BioWhittaker), 50 µg of vancomycin per ml, and 10 µg of gentamicin per ml. Cells were maintained in a 37°C, 5%
CO2 incubator and split every 2 days by gentle scraping.
Infection and culture of macrophages.
Macrophages were
plated at a density of either 4 × 104 cells/well on
96-well trays (0.32-cm2 growth area; Corning Costar
Corporation, Cambridge, Mass.) or 2 × 105 cells/well
on 24-well trays (1.9-cm2 growth area; Corning) and
incubated overnight prior to infection. In some experiments,
macrophages were plated overnight at 2 × 104
cells/well on Lab-Tek chamber slides (0.32-cm2 growth area;
Nunc Inc., Naperville, Ill.) prior to infection. Macrophages were
infected by incubating cells for 2 h with various doses of
C. pneumoniae in 50 µl (96-well trays) or 200 µl
(24-well trays) of RPMI 1640-10% FBS. Cells then were washed twice
with phosphate-buffered saline (PBS; BioWhittaker) and incubated for 24 h in 200 µl (96-well trays) or 500 µl (24-well trays) of
RPMI 1640-10% FBS in the presence or absence of heparin (100 U/ml) and/or various doses of LDL. Prior to infection in some experiments, chlamydiae were incubated in RPMI medium for 1 h either in a
100°C water bath or at 37°C with 0.25 M sodium periodate in 0.25 M
sodium acetate buffer (pH 5.5). In other experiments, macrophages were cultured with LDL in the presence or absence of cLPS and/or lipid X. All buffers were brought to 37°C before addition to macrophages. Trypan blue staining showed that none of the treatments affected macrophage viability at 24 h (>95% of macrophages were viable).
Quantitation of foam cell formation.
Macrophages were washed
twice with PBS, fixed for 15 min in 2% paraformaldehyde, and stained
for 15 min in 1% oil red O (in 60% isopropanol). Cells then were
washed three times in PBS and examined by light (×200) or dark-field
(×400) microscopy (Diaphot 200 or Optiphot microscope; Nikon, Garden
City, N.Y.). Cholesteryl ester-laden macrophages were scored by
previously established criteria (17, 42).
Quantitation of macrophage cholesteryl ester content.
Macrophage cholesteryl ester content was quantitated by a modification
of the method of Gamble et al. (11). Briefly, macrophages were fixed in 0.5% paraformaldehyde, washed three times with PBS, and
incubated in 200 µl (24-well trays) of absolute ethanol for 30 min at
4°C to extract cellular lipids. Cholesterol content was determined by
incubating 20 µl of ethanol-extracted lipids with 180 µl of assay
solution (total cholesterol) (11) or 180 µl of assay
solution lacking cholesterol esterase (free cholesterol) for 1 h
at 37°C and then measuring fluorescence (HTS-7000 microplate fluorometer; 340-nm excitation, 405-nm emission; Perkin-Elmer, Foster
City, Calif.). Total and free cholesterol contents were calculated by
using cholesteryl oleate and cholesterol as standards. Cholesteryl
ester content was calculated by subtracting free cholesterol from total
cholesterol for each sample and is reported as mean ± standard
deviation (SD). Lipid-extracted cells were dissolved in 0.1% sodium
dodecyl sulfate-0.1 M NaOH for 30 min, and total cell protein was
determined by the use of a Lowry protein assay kit (DC Protein Assay;
Bio-Rad).
 |
RESULTS |
C. pneumoniae induces foam cell formation and
cholesteryl ester accumulation by RAW macrophages.
RAW macrophages
exposed to C. pneumoniae accumulated cytoplasmic cholesteryl
ester droplets in the presence of exogenous LDL (Fig.
1) in a manner similar to that previously
observed for human macrophages (20). C. pneumoniae-infected macrophages also accumulated increasing levels
of cholesteryl esters when cultured with increasing concentrations of
LDL (Fig. 2). Furthermore, infection of
macrophages with increasing doses of C. pneumoniae resulted
in higher levels of cholesteryl ester formation (Fig.
3). As with human macrophages, RAW
macrophages did not accumulate cholesteryl esters when cultured in the
presence of heparin (Fig. 3), which binds LDL and prevents its
association with a native LDL receptor (13). Heparin also inhibited baseline accumulation of cholesteryl esters by uninfected macrophages cultured with exogenous LDL (Fig. 3). In contrast, C. pneumoniae-induced foam cell formation was not inhibited when cells were cultured with fucoidan, which inhibits modified LDL uptake
by class A scavenger receptors (14), or in the presence of
the antioxidant butylated hydroxytoluene (not shown).

View larger version (110K):
[in this window]
[in a new window]
|
FIG. 1.
Foam cell formation by uninfected (A) and infected (B)
RAW macrophages. Cells were infected (MOI = 1) or not infected for
2 h, washed twice, and incubated with 100 µg of LDL per ml for
24 h. Micrographs show oil red O-stained macrophages containing
cytoplasmic neutral lipid droplets (magnification, ×400; dark-field
microscopy).
|
|

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 2.
Cholesteryl ester levels in uninfected (open circles)
and C. pneumoniae-infected (solid circles) macrophages.
Cells were infected (MOI = 2) or not infected for 2 h, washed
twice, and incubated with various doses of LDL for 24 h.
Cholesteryl ester levels were normalized to protein content. Data are
representative of three experiments and are reported as means of
triplicates with SD. *, statistically significant difference compared
with infected samples cultured without exogenous LDL, P < 0.05 (t test).
|
|

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 3.
Cholesteryl ester levels in heparin-treated (open
circles) and untreated (solid circles) macrophages. Cells were infected
with C. pneumoniae at various MOIs for 2 h, washed
twice, and incubated with 100 µg of LDL per ml for 24 h.
Cholesteryl ester levels were normalized to protein content. Data are
representative of three experiments and are reported as means of
triplicates with SD. *, statistically significant difference compared
with uninfected, non-heparin-treated control, P < 0.05 (t test).
|
|
Exposure of C. pneumoniae to periodate but not elevated
temperatures inhibits macrophage foam cell formation.
To
characterize the C. pneumoniae components involved in
inducing macrophage foam cell formation, chlamydiae were exposed to
elevated temperatures or periodate before being added to macrophages. Figure 4 shows that incubation of
C. pneumoniae for 1 h at 100°C followed by cooling to
37°C did not inhibit the organism's capacity to induce foam cell
formation, although exposure of macrophages to only medium treated in a
similar manner did cause ~18% of macrophages to accumulate neutral
lipids. However, C. pneumoniae that was treated for 1 h
with 25 mM sodium periodate, which has been shown to oxidize antigenic
carbohydrate residues on cLPS (3, 5), exhibited
significantly reduced capacity for foam cell formation (Fig. 4). In a
separate experiment designed to test if any
Chlamydia-secreted products caused induce foam cell
formation, chlamydiae were centrifuged and supernatants were added to
macrophages in the presence of LDL; Chlamydia supernatants
failed to induce macrophage foam cell formation (<10% oil red
O-positive cells).

View larger version (12K):
[in this window]
[in a new window]
|
FIG. 4.
Foam cell formation by uninfected (solid bars) and
C. pneumoniae-infected (open bars) macrophages. Chlamydiae
(MOI = 2) were incubated in RPMI medium for 1 h at 4°C (No
Rx.), at 100°C (Heat), or with 0.25 M sodium periodate at 37°C
(Periodate) before infection, cultured in the presence of 100 µg of
LDL per ml, and stained with oil red O. About 500 cells were counted
from each well. Data are representative of three experiments and are
reported as means of triplicates with SD. *, statistically
significant difference compared with untreated, infected and
heat-treated, infected samples, P < 0.001.
|
|
Chlamydial LPS is sufficient to induce macrophage foam cell
formation and cholesteryl ester accumulation.
To test whether
purified cLPS could induce foam cell formation, macrophages were
exposed to cLPS at various doses and incubated in the presence of LDL.
The results indicate that cLPS was sufficient to induce cholesteryl
ester accumulation (Fig. 5A) and foam
cell formation (Fig. 5B).

View larger version (12K):
[in this window]
[in a new window]
|
FIG. 5.
Cholesteryl ester levels in (A) and foam cell formation
by (B) cLPS-treated macrophages. Cells were exposed to various
concentrations of cLPS for 1 h and cultured in the presence of 100 µg of LDL per ml for 24 h. Data are representative of three
experiments and are reported as means of triplicates with SD. *,
statistically significant difference compared with untreated samples,
P < 0.05; **, statistically significant difference
compared with untreated samples, P < 0.005.
|
|
Lipid X inhibits C. pneumoniae- and cLPS-induced foam
cell formation.
To determine whether a specific LPS antagonist
could inhibit C. pneumoniae-induced macrophage lipid uptake,
infected and uninfected macrophages were cultured in the presence of
various concentrations of lipid X, a monosaccharide precursor of the
lipid A component of LPS (35). Figure
6A shows that lipid X inhibited foam cell formation by C. pneumoniae-infected macrophages in a
dose-dependent manner and also inhibited cLPS-induced foam cell
formation (Fig. 6B).

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 6.
Effect of lipid X on foam cell formation by C. pneumoniae-infected (A) and cLPS-exposed (B) macrophages. (A)
Uninfected (open circles) or infected (MOI = 2; closed circles)
cells were washed and incubated with 100 µg of LDL per ml for 20 h in the presence or absence of various concentrations of lipid X. (B)
Untreated (open circles) or cLPS-treated (100 ng/ml; closed circles)
cells were incubated with 100 µg of LDL per ml for 20 h in the
presence or absence of various concentrations of lipid X. Macrophages
were fixed and stained with oil red O, and about 500 cells were counted
from each well. Data are representative of three experiments and are
reported as means of triplicates with SD. *, statistically
significant difference compared with untreated samples,
P < 0.005.
|
|
 |
DISCUSSION |
Recent appreciation of atherosclerosis as an inflammatory disease
(1, 12, 28, 29, 38) has renewed interest in possible infectious etiologies of atherogenesis. Atherosclerosis and chlamydial diseases share some interesting similarities, including the fact that
they are chronic, subclinical, and inflammatory in nature (39,
47), with macrophage activation playing a key role in the
inflammatory process (40). Formation of macrophage foam cells in the arterial intima is the hallmark of early lesions in
atherosclerosis (39), and the pivotal step in foam cell
formation is the uptake of excess cholesterol from LDL (4).
Recently, C. pneumoniae was shown to induce macrophage foam
cell formation in the presence of exogenous LDL (20),
suggesting a causal role for the organism in atherogenesis. The present
work further characterizes C. pneumoniae-induced foam cell
formation by determining the C. pneumoniae component
responsible for macrophage lipid accumulation. Chlamydiae incubated for
1 h at 100°C retained the capacity to induce foam cell
formation, suggesting that the C. pneumoniae component that
induced lipid accumulation was nonproteinaceous and heat stable (Fig.
4). In contrast, chlamydiae treated with periodate, which oxidizes
antigenic carbohydrate residues on cLPS, had decreased capacity to
induce macrophage foam cell formation (Fig. 4), suggesting that the
C. pneumoniae heat-stable component causing macrophage lipid
accumulation was cLPS. Indeed, cLPS extracted from chlamydiae was
sufficient to induce macrophage foam cell formation and cholesteryl
ester accumulation (Fig. 5), and C. pneumoniae- or
cLPS-induced lipid uptake was inhibited by the LPS antagonist lipid X
(Fig. 6). These data indicate that cLPS is a C. pneumoniae
component that induces macrophage foam cell formation and suggest that
inhibiting the activity of cLPS in vivo with monoclonal antibodies or
LPS analogues may be sufficient to reduce C. pneumoniae-induced foam cell formation and atheroma development.
Persistence of cLPS in the atheroma, either within intact C. pneumoniae-infected cells or in the exogenous subendothelial milieu following cell lysis, may promote atherosclerosis by continual macrophage activation and foam cell formation. Indeed, circulating cLPS-specific immune complexes, which may result from cLPS shedding from the atheroma, have been detected in patients with coronary heart
disease (27). Compared to enterobacterial LPS, cLPS is a
weak inducer of tumor necrosis factor alpha secretion (18), and the decreased capacity of cLPS to induce an acute inflammatory response may be necessary for chlamydial survival and establishment of
chronic infection (2). In contrast, cLPS and enterobacterial LPS may be equally effective in inducing other macrophage activities that are not central to bacterial clearance, such as lipid uptake and
foam cell formation. LPSs extracted from E. coli and
Salmonella typhimurium have been shown to induce macrophage
lipid accumulation when cultured in the presence of native LDL (9,
33), but the relative contribution to foam cell formation of
endotoxins isolated from various bacteria is not known. Although
endotoxin-mediated foam cell formation is not restricted to cLPS, it is
improbable that other gram-negative organisms can invade and survive
within the arterial intima to provide a continual source of antigen
necessary to induce chronic inflammation and foam cell formation;
unlike other gram-negative bacteria, C. pneumoniae has been
detected within and isolated from atheromas (7, 25, 36), and
it can survive and multiply within all cell types found in the atheroma (12). However, gram-negative septicemia may provide sporadic infiltration of enterobacterial LPS into the arterial intima
(26), and therefore a possible role for enterobacterial LPS
in foam cell formation in vivo cannot be discounted. Studies are under way to compare the effects of enterobacterial LPS versus cLPS and
C. pneumoniae on foam cell formation in vivo in a murine
model of atherosclerosis.
 |
ACKNOWLEDGMENTS |
We thank Donna Paulnock, Mary Lokuta, and Joy Stuckey for
providing advice regarding the RAW-264.7 cells, Charles Schobert and
Adam Pleister for helping in propagating C. pneumoniae,
Colleen Kane for help with dark-field microscopy, and Loren Denlinger for reviewing the manuscript.
This work was supported in part by NIH grants AI 19782 and AI 34617.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Dept. of Medical
Microbiology & Immunology, University of Wisconsin Medical School, 471 SMI, 1300 University Ave., Madison, WI 53706. Phone: (608) 263-2494. Fax: (608) 262-8418. E-mail: gibyrne{at}facstaff.wisc.edu.
Editor:
R. N. Moore
 |
REFERENCES |
| 1.
|
Blum, A., and H. Miller.
1996.
The role of inflammation in atherosclerosis.
Isr. J. Med. Sci.
32:1059-1065[Medline].
|
| 2.
|
Brade, H.,
W. Brabetz,
L. Brade,
O. Holst,
S. Lobau,
M. Mucakova,
U. Mamat,
A. Rozalski,
K. Zych, and P. Kosma.
1997.
Chlamydial lipopolysaccharide.
J. Endotoxin Res.
4:67-84.
|
| 3.
|
Brade, L.,
S. Schramek,
U. Schade, and H. Brade.
1986.
Chemical, biological, and immunochemical properties of the Chlamydia psittaci lipopolysaccharide.
Infect. Immun.
54:568-574[Abstract/Free Full Text].
|
| 4.
|
Brown, M., and J. Goldstein.
1983.
Lipoprotein metabolism in the macrophage.
Annu. Rev. Biochem.
52:223-261[Medline].
|
| 5.
|
Caldwell, H., and P. Hitchcock.
1984.
Monoclonal antibody against a genus-specific antigen of Chlamydia species: location of the epitope on chlamydial lipopolysaccharide.
Infect. Immun.
44:306-314[Abstract/Free Full Text].
|
| 6.
|
Caldwell, H. D.,
J. Kromhout, and J. Schachter.
1981.
Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis.
Infect. Immun.
31:1161-1176[Abstract/Free Full Text].
|
| 7.
|
Campbell, L.,
E. O. Brien,
A. Cappuccio,
C. Kuo,
S. Wang,
D. Stewart,
D. Patton,
P. Cummings, and J. Grayston.
1995.
Detection of Chlamydia pneumoniae TWAR in human coronary atherectomy tissues.
J. Infect. Dis.
172:585-588[Medline].
|
| 8.
|
Esterbauer, H.,
J. Gebicki,
H. Puhl, and G. Jurgens.
1992.
The role of lipid peroxidation and antioxidants in oxidative modification of LDL.
Free Radic. Biol. Med.
13:341-390[Medline].
|
| 9.
|
Funk, J.,
K. Feingold,
A. Moser, and C. Grunfeld.
1993.
Lipopolysaccharide stimulation of RAW 264.7 macrophages induces lipid accumulation and foam cell formation.
Atherosclerosis
98:67-82[Medline].
|
| 10.
|
Galanos, C.,
O. Luderitz, and O. Westphal.
1969.
A new method for the extraction of R lipopolysaccharides.
Eur. J. Biochem.
9:245-249[Medline].
|
| 11.
|
Gamble, W.,
M. Vaughan,
H. Kruth, and J. Avigan.
1978.
Procedure for determination of free and total cholesterol in micro- or nanogram amounts suitable for studies with cultured cells.
J. Lipid Res.
19:1068-1070[Abstract].
|
| 12.
|
Gaydos, C.,
J. Summersgill,
N. Sahney,
J. Ramirez, and T. Quinn.
1996.
Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells.
Infect. Immun.
64:1614-1620[Abstract].
|
| 13.
|
Goldstein, J.,
S. Basu,
G. Brunschede, and M. Brown.
1976.
Release of low density lipoprotein from its cell surface receptor by sulfated glycosaminoglycans.
Cell
7:85-95[Medline].
|
| 14.
|
Goldstein, J.,
H. Hoff,
Y. Ho,
S. Basu, and M. Brown.
1981.
Stimulation of cholesteryl ester synthesis in macrophages by extracts of atherosclerotic human aortas and complexes of albumin/cholesteryl esters.
Arteriosclerosis
1:210-226[Abstract/Free Full Text].
|
| 15.
|
Gupta, S.,
E. Leatham,
D. Carrington,
M. Mendall,
J. Kaski, and J. Camm.
1997.
Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction.
Circulation
96:404-407[Abstract/Free Full Text].
|
| 16.
|
Gurfinkel, E.,
G. Bozovich,
A. Daroca,
E. Beck, and B. Mautner.
1997.
Randomized trial of roxithromycin in non-Q-wave coronary syndromes Roxis pilot study.
Lancet
350:404-407[Medline].
|
| 17.
|
Huh, H.,
S. Pearce,
L. Yesner,
J. Schindler, and R. Silverstein.
1996.
Regulated expression of CD36 during monocyte-to-macrophage differentiation: potential role of CD36 in foam cell formation.
Blood
87:2020-2028[Abstract/Free Full Text].
|
| 18.
|
Ingalls, R.,
P. Rice,
N. Qureshi,
K. Takayama,
J. Shin-Lin, and D. Golenbock.
1995.
The inflammatory cytokine response to Chlamydia trachomatis infection is endotoxin mediated.
Infect. Immun.
63:3125-3130[Abstract].
|
| 19.
|
Jackson, I.,
L. Campbell,
C. Kuo,
D. Rodriguez,
A. Lee, and J. Grayston.
1997.
Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen.
J. Infect. Dis.
176:292-295[Medline].
|
| 20.
|
Kalayoglu, M., and G. Byrne.
1998.
Induction of macrophage foam cell formation by Chlamydia pneumoniae.
J. Infect. Dis.
177:725-729[Medline].
|
| 21.
|
Kannel, W., and P. Sytkowski.
1987.
Atherosclerosis risk factors.
Pharmacol. Ther.
32:207-235[Medline].
|
| 22.
|
Kaukoranta-Tolvanen, S.,
A. Teppo,
K. Kaitinen,
P. Saikku,
K. Linnavuori, and M. Leinonen.
1996.
Growth of Chlamydia pneumoniae in cultured human peripheral blood mononuclear cells and induction of a cytokine response.
Microb. Pathog.
21:215-221[Medline].
|
| 23.
|
Kuo, C.,
A. Gown,
E. Benditt, and J. Grayston.
1993.
Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain.
Arterioscler. Thromb.
13:1501-1504[Abstract/Free Full Text].
|
| 24.
|
Kuo, C.,
J. Grayston,
L. Campbell,
Y. Goo,
R. Wissler, and E. Benditt.
1995.
Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15-34 years old).
Proc. Natl. Acad. Sci. USA
92:6911-6914[Abstract/Free Full Text].
|
| 25.
|
Kuo, C.,
A. Shor,
L. Campbell,
H. Fukushi,
D. Patton, and T. Grayston.
1993.
Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries.
J. Infect. Dis.
167:841-849[Medline].
|
| 26.
|
Liao, W.
1996.
Endotoxin: possible roles in initiation and development of atherosclerosis.
J. Lab. Clin. Med.
128:452-460[Medline].
|
| 27.
|
Linnanmaki, E.,
M. Leinonen,
K. Mattila,
M. Nieminen,
V. Valtonen, and P. Saikku.
1993.
Chlamydia pneumoniae specific circulating immune complexes in patients with chronic coronary heart disease.
Circulation
87:1130-1134[Abstract/Free Full Text].
|
| 28.
|
Maseri, A.
1997.
Inflammation, atherosclerosis, and ischemic events exploring the hidden side of the moon.
N. Engl. J. Med.
336:1014-1016[Free Full Text].
|
| 29.
|
Mendall, M.,
P. Patel,
L. Ballam,
D. Strachan, and T. Northfield.
1996.
C-reactive protein and its relation to cardiovascular risk factors a population based cross sectional study.
Br. Med. J.
312:1061-1065[Abstract/Free Full Text].
|
| 30.
|
Moazed, T.,
C. Kuo,
J. Grayston, and L. Campbell.
1997.
Murine models of Chlamydia pneumoniae infection and atherosclerosis.
J. Infect. Dis.
175:883-890[Medline].
|
| 31.
|
Muhlestein, J.,
J. Anderson,
E. Hammond,
L. Zhao,
S. Trehan,
E. Schwobe, and J. Carlquist.
1998.
Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model.
Circulation
97:633-636[Abstract/Free Full Text].
|
| 32.
|
Murakami, T., and N. Yamada.
1996.
Modification of macrophage function and effects on atherosclerosis.
Curr. Opin. Lipidol.
7:320-323[Medline].
|
| 33.
|
Oiknine, J., and M. Aviram.
1992.
Increased susceptibility to activation and increased uptake of low density lipoprotein by cholesterol-loaded macrophages.
Arterioscler. Thromb.
12:745-753[Abstract/Free Full Text].
|
| 34.
|
Qureshi, N.,
P. Mascagni,
E. Ribi, and K. Takayama.
1985.
Monophosphoryl lipid A obtained from lipopolysaccharides of Salmonella minnesota R595.
J. Biol. Chem.
260:5271-5278[Abstract/Free Full Text].
|
| 35.
|
Raetz, C.
1990.
Biochemistry of endotoxins.
Annu. Rev. Biochem.
59:129-170[Medline].
|
| 36.
|
Ramirez, J.,
S. Ahkee,
J. Summersgill,
B. Ganzer,
L. Ogden,
T. Quinn,
C. Goydos,
L. Bobo,
M. Hammerschlag,
P. Roblow,
W. Lebar,
J. Grayston,
L. Campbell,
D. Patton,
D. Dean, and J. Schachter.
1996.
Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis.
Ann. Intern. Med.
125:979-982[Abstract/Free Full Text].
|
| 37.
|
Redgrave, T.,
D. Roberts, and C. West.
1975.
Separation of plasma lipoproteins by density-gradient ultracentrifugation.
Anal. Biochem.
65:42-49[Medline].
|
| 38.
|
Ridker, P.,
M. Cushman,
M. Stampfer,
R. Tracy, and C. Hennekens.
1997.
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
N. Engl. J. Med.
336:973-979[Abstract/Free Full Text].
|
| 39.
|
Ross, R.
1993.
The pathogenesis of atherosclerosis: a perspective for the 1990s.
Nature
362:801-809[Medline].
|
| 40.
|
Saikku, P.
1993.
Chlamydia pneumoniae infection as a risk factor in acute myocardial infarction.
Eur. Heart J.
14:62-65.
|
| 41.
|
Saikku, P.,
M. Leinonen,
L. Tenkanen,
E. Linnanmaki,
M.-R. Ekman,
V. Manninen,
M. Manttari,
M. Frick, and J. Huttunen.
1992.
Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study.
Ann. Intern. Med.
116:273-278.
|
| 42.
|
Schaffner, T.,
K. Taylor,
E. Bartucci,
K. Fischer-Dzoga,
J. Beeson,
S. Glagov, and R. Wissler.
1980.
Arterial foam cells with distinctive immunomorphologic and histochemical features of macrophages.
Am. J. Pathol.
100:57-80[Abstract].
|
| 43.
|
Shor, A.,
C. Kuo, and D. Patton.
1992.
Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques.
S. Afr. Med. J.
82:158-161[Medline].
|
| 44.
|
Stehbens, W.
1997.
The pathogenesis of atherosclerosis a critical evaluation of the evidence.
Cardiovasc. Pathol.
6:123-153.
|
| 45.
|
Strong, J.
1995.
Natural history and risk factors for early human atherogenesis.
Clin. Chem.
41:143-148.
|
| 46.
|
Superko, H.
1995.
New aspects of risk factors for the development of atherosclerosis, including small low-density lipoprotein, homocysteine, and lipoprotein(a).
Curr. Opin. Cardiol.
10:347-354[Medline].
|
| 47.
|
Ward, M.
1995.
The immunobiology and immunopathology of chlamydial infections.
APMIS
103:769-796[Medline].
|
| 48.
|
Yokude, M., and T. Kita.
1995.
The macrophage and its role in atherogenesis.
Intern. Med.
34:281-283[Medline].
|
Infection and Immunity, November 1998, p. 5067-5072, Vol. 66, No. 11
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Lajunen, T., Vikatmaa, P., Bloigu, A., Ikonen, T., Lepantalo, M., Pussinen, P. J., Saikku, P., Leinonen, M.
(2008). Chlamydial LPS and high-sensitivity CRP levels in serum are associated with an elevated body mass index in patients with cardiovascular disease. Innate Immunity
14: 375-382
[Abstract]
-
Chen, S., Sorrentino, R., Shimada, K., Bulut, Y., Doherty, T. M., Crother, T. R., Arditi, M.
(2008). Chlamydia pneumoniae-Induced Foam Cell Formation Requires MyD88-Dependent and -Independent Signaling and Is Reciprocally Modulated by Liver X Receptor Activation. J. Immunol.
181: 7186-7193
[Abstract]
[Full Text]
-
Jiang, S.-J., Kuo, C.-C., Berry, M. W., Lee, A. W., Campbell, L. A.
(2008). Identification and Characterization of Chlamydia pneumoniae-Specific Proteins That Activate Tumor Necrosis Factor Alpha Production in RAW 264.7 Murine Macrophages. Infect. Immun.
76: 1558-1564
[Abstract]
[Full Text]
-
Kim, D. K., Kim, H. J., Han, S. H., Lee, J. E., Moon, S. J., Kim, B. S., Kang, S.-W., Choi, K. H., Lee, H. Y., Han, D.-S.
(2008). Chlamydia pneumoniae accompanied by inflammation is associated with the progression of atherosclerosis in CAPD patients: a prospective study for 3 years. Nephrol Dial Transplant
23: 1011-1018
[Abstract]
[Full Text]
-
Tsutsumi-Ishii, Y., Shimada, K., Daida, H., Toman, R., Nagaoka, I.
(2008). Low potency of Chlamydophila LPS to activate human mononuclear cells due to its reduced affinities for CD14 and LPS-binding protein. Int Immunol
20: 199-208
[Abstract]
[Full Text]
-
Cao, F., Castrillo, A., Tontonoz, P., Re, F., Byrne, G. I.
(2007). Chlamydia pneumoniae-Induced Macrophage Foam Cell Formation Is Mediated by Toll-Like Receptor 2. Infect. Immun.
75: 753-759
[Abstract]
[Full Text]
-
Volanen, I., Jarvisalo, M. J., Vainionpaa, R., Arffman, M., Kallio, K., Angle, S., Ronnemaa, T., Viikari, J., Marniemi, J., Raitakari, O. T., Simell, O.
(2006). Increased Aortic Intima-Media Thickness in 11-Year-Old Healthy Children With Persistent Chlamydia pneumoniae Seropositivity. Arterioscler. Thromb. Vasc. Bio.
26: 649-655
[Abstract]
[Full Text]
-
Yang, X., Coriolan, D., Schultz, K., Golenbock, D. T., Beasley, D.
(2005). Toll-Like Receptor 2 Mediates Persistent Chemokine Release by Chlamydia pneumoniae-Infected Vascular Smooth Muscle Cells. Arterioscler. Thromb. Vasc. Bio.
25: 2308-2314
[Abstract]
[Full Text]
-
Arno, G, Kaski, J C, Smith, D A, Akiyu, J P, Hughes, S E, Baboonian, C
(2005). Matrix metalloproteinase-9 expression is associated with the presence of Chlamydia pneumoniae in human coronary atherosclerotic plaques. Heart
91: 521-525
[Abstract]
[Full Text]
-
Rupp, J., Hellwig-Burgel, T., Wobbe, V., Seitzer, U., Brandt, E., Maass, M.
(2005). Chlamydia pneumoniae infection promotes a proliferative phenotype in the vasculature through Egr-1 activation in vitro and in vivo. Proc. Natl. Acad. Sci. USA
102: 3447-3452
[Abstract]
[Full Text]
-
Netea, M. G., Kullberg, B. J., Jacobs, L. E. H., Verver-Jansen, T. J. G., van der Ven-Jongekrijg, J., Galama, J. M. D., Stalenhoef, A. F. H., Dinarello, C. A., Van der Meer, J. W. M.
(2004). Chlamydia pneumoniae Stimulates IFN-{gamma} Synthesis through MyD88-Dependent, TLR2- and TLR4-Independent Induction of IL-18 Release. J. Immunol.
173: 1477-1482
[Abstract]
[Full Text]
-
Khovidhunkit, W., Kim, M.-S., Memon, R. A., Shigenaga, J. K., Moser, A. H., Feingold, K. R., Grunfeld, C.
(2004). Thematic review series: The Pathogenesis of Atherosclerosis. Effects of infection and inflammation on lipid and lipoprotein metabolism mechanisms and consequences to the host. J. Lipid Res.
45: 1169-1196
[Abstract]
[Full Text]
-
Carabeo, R. A., Mead, D. J., Hackstadt, T.
(2003). Golgi-dependent transport of cholesterol to the Chlamydia trachomatis inclusion. Proc. Natl. Acad. Sci. USA
100: 6771-6776
[Abstract]
[Full Text]
-
Kalayoglu, M. V., Galvan, C., Mahdi, O. S., Byrne, G. I., Mansour, S.
(2003). Serological Association Between Chlamydia pneumoniae Infection and Age-Related Macular Degeneration. Arch Ophthalmol
121: 478-482
[Abstract]
[Full Text]
-
Kalayoglu, M. V., Libby, P., Byrne, G. I.
(2002). Chlamydia pneumoniae as an Emerging Risk Factor in Cardiovascular Disease. JAMA
288: 2724-2731
[Abstract]
[Full Text]
-
Nieto, F.
(2002). Commentary: The epidemiology of self-deprecation. Int J Epidemiol
31: 1124-1127
[Full Text]
-
Mahdi, O. S., Horne, B. D., Mullen, K., Muhlestein, J. B., Byrne, G. I.
(2002). Serum Immunoglobulin G Antibodies to Chlamydial Heat Shock Protein 60 but Not to Human and Bacterial Homologs Are Associated With Coronary Artery Disease. Circulation
106: 1659-1663
[Abstract]
[Full Text]
-
Netea, M. G., Kullberg, B. J., Demacker, P. N. M., Jacobs, L. E. H., Verver-Jansen, T. J. G., Hijmans, A., van Tits, L. H. J., Hoenderop, J. G. J., Willems, P. H. G. M., Van der Meer, J. W. M., Stalenhoef, A. F. H.
(2002). Native LDL potentiate TNF{alpha} and IL-8 production by human mononuclear cells. J. Lipid Res.
43: 1065-1071
[Abstract]
[Full Text]
-
Baranova, I., Vishnyakova, T., Bocharov, A., Chen, Z., Remaley, A. T., Stonik, J., Eggerman, T. L., Patterson, A. P.
(2002). Lipopolysaccharide Down Regulates Both Scavenger Receptor B1 and ATP Binding Cassette Transporter A1 in RAW Cells. Infect. Immun.
70: 2995-3003
[Abstract]
[Full Text]
-
FONG, I. W.
(2002). Infections and their role in atherosclerotic vascular disease. Journal of the American Dental Association
133: 7S-13S
[Abstract]
[Full Text]
-
Tintut, Y., Patel, J., Territo, M., Saini, T., Parhami, F., Demer, L. L.
(2002). Monocyte/Macrophage Regulation of Vascular Calcification In Vitro. Circulation
105: 650-655
[Abstract]
[Full Text]
-
Bulut, Y., Faure, E., Thomas, L., Karahashi, H., S. Michelsen, K., Equils, O., Morrison, S. G., Morrison, R. P., Arditi, M.
(2002). Chlamydial Heat Shock Protein 60 Activates Macrophages and Endothelial Cells Through Toll-Like Receptor 4 and MD2 in a MyD88-Dependent Pathway. J. Immunol.
168: 1435-1440
[Abstract]
[Full Text]
-
Xu, X. H., Shah, P. K., Faure, E., Equils, O., Thomas, L., Fishbein, M. C., Luthringer, D., Xu, X.-P., Rajavashisth, T. B., Yano, J., Kaul, S., Arditi, M.
(2001). Toll-Like Receptor-4 Is Expressed by Macrophages in Murine and Human Lipid-Rich Atherosclerotic Plaques and Upregulated by Oxidized LDL. Circulation
104: 3103-3108
[Abstract]
[Full Text]
-
Haranaga, S., Yamaguchi, H., Friedman, H., Izumi, S.-i., Yamamoto, Y.
(2001). Chlamydia pneumoniae Infects and Multiplies in Lymphocytes In Vitro. Infect. Immun.
69: 7753-7759
[Abstract]
[Full Text]
-
Gigliotti Rothfuchs, A., Gigliotti, D., Palmblad, K., Andersson, U., Wigzell, H., Rottenberg, M. E.
(2001). IFN-{alpha}{beta}-Dependent, IFN-{gamma} Secretion by Bone Marrow-Derived Macrophages Controls an Intracellular Bacterial Infection. J. Immunol.
167: 6453-6461
[Abstract]
[Full Text]
-
Libby, P.
(2001). Current Concepts of the Pathogenesis of the Acute Coronary Syndromes. Circulation
104: 365-372
[Full Text]
-
Coombes, B. K., Mahony, J. B.
(2001). cDNA Array Analysis of Altered Gene Expression in Human Endothelial Cells in Response to Chlamydia pneumoniae Infection. Infect. Immun.
69: 1420-1427
[Abstract]
[Full Text]
-
Muhlestein, J. B., Anderson, J. L., Carlquist, J. F., Salunkhe, K., Horne, B. D., Pearson, R. R., Bunch, T. J., Allen, A., Trehan, S., Nielson, C.
(2000). Randomized Secondary Prevention Trial of Azithromycin in Patients With Coronary Artery Disease : Primary Clinical Results of the ACADEMIC Study. Circulation
102: 1755-1760
[Abstract]
[Full Text]
-
Morre, S A, Stooker, W, Lagrand, W K, van den Brule, A J C, Niessen, H W M
(2000). Microorganisms in the aetiology of atherosclerosis. J. Clin. Pathol.
53: 647-654
[Abstract]
[Full Text]
-
Fong, I. W.
(2000). Emerging relations between infectious diseases and coronary artery disease and atherosclerosis. CMAJ
163: 49-56
[Abstract]
[Full Text]
-
Kitchens, R. L., Wolfbauer, G., Albers, J. J., Munford, R. S.
(1999). Plasma Lipoproteins Promote the Release of Bacterial Lipopolysaccharide from the Monocyte Cell Surface. J. Biol. Chem.
274: 34116-34122
[Abstract]
[Full Text]
-
Fong, I. W., Chiu, B., Viira, E., Jang, D., Mahony, J. B.
(1999). De Novo Induction of Atherosclerosis by Chlamydia pneumoniae in a Rabbit Model. Infect. Immun.
67: 6048-6055
[Abstract]
[Full Text]
-
Coombes, B. K., Mahony, J. B.
(1999). Chlamydia pneumoniae Infection of Human Endothelial Cells Induces Proliferation of Smooth Muscle Cells via an Endothelial Cell-Derived Soluble Factor(s). Infect. Immun.
67: 2909-2915
[Abstract]
[Full Text]
-
Sasu, S., LaVerda, D., Qureshi, N., Golenbock, D. T., Beasley, D.
(2001). Chlamydia pneumoniae and Chlamydial Heat Shock Protein 60 Stimulate Proliferation of Human Vascular Smooth Muscle Cells via Toll-Like Receptor 4 and p44/p42 Mitogen-Activated Protein Kinase Activation. Circ. Res.
89: 244-250
[Abstract]
[Full Text]